The Swiss Tropical and Public Health Institute (Swiss TPH) has helped create an international partnership of several leading leprosy groups. Sunday is World Leprosy Day.
Supported by the World Health Organization (WHO), the new Global Partnership for Zero Leprosyexternal link brings together organizations like the Swiss-based Novartis Foundation, the International Federation of Anti-Leprosy Associations (ILEP), the International Association for Integration, Dignity and Economic Advancement (IDEA), national leprosy programmes and academic institutions.
Peter Steinmann of Swiss TPH represents the scientific community in the creation of this partnership.
“Swiss TPH is actively involved in establishing the proof-of-concept of novel interventions against leprosy,” said Steinmann in a media releaseexternal link. “The new partnership offers a unique platform to harness the results of the best science for the benefit of the world’s poorest people.”
The Global Partnership for Zero Leprosy will coordinate action in three key areas: 1) diagnostic research and therapeutic tools to prevent spread of leprosy; 2) technical assistance and expertise to strengthen existing national programmes and accelerate translation of new evidence; and (3) advocacy and fundraising.
Despite the availability of effective multi-drug therapy, the number of newly diagnosed leprosy patients has remained above 200,000 per year for the last decade, including thousands of children, according to Swiss TPH. The institute blames inadequate resources and stigma.
swissinfo.ch/sm
Neuer Inhalt
Horizontal Line
swissinfo EN
The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.
All rights reserved. The content of the website by swissinfo.ch is copyrighted. It is intended for private use only. Any other use of the website content beyond the use stipulated above, particularly the distribution, modification, transmission, storage and copying requires prior written consent of swissinfo.ch. Should you be interested in any such use of the website content, please contact us via contact@swissinfo.ch.
As regards the use for private purposes, it is only permitted to use a hyperlink to specific content, and to place it on your own website or a website of third parties. The swissinfo.ch website content may only be embedded in an ad-free environment without any modifications. Specifically applying to all software, folders, data and their content provided for download by the swissinfo.ch website, a basic, non-exclusive and non-transferable license is granted that is restricted to the one-time downloading and saving of said data on private devices. All other rights remain the property of swissinfo.ch. In particular, any sale or commercial use of these data is prohibited.
